{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:06:13Z","timestamp":1793023573213,"version":"4.5.0"},"reference-count":209,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41582-026-01224-9","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:09:15Z","timestamp":1781712555000},"page":"549-563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ten years of disease-modifying therapy in spinal muscular atrophy: lessons learned and future directions"],"prefix":"10.1038","volume":"22","author":[{"given":"Eugenio","family":"Mercuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9351-7054","authenticated-orcid":false,"given":"Richard S.","family":"Finkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9102-5232","authenticated-orcid":false,"given":"Francesco","family":"Muntoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"1224_CR1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","volume":"8","author":"E Mercuri","year":"2022","unstructured":"Mercuri, E., Sumner, C. J., Muntoni, F., Darras, B. T. & Finkel, R. S. Spinal muscular atrophy. Nat. Rev. Dis. Primers 8, 52 (2022).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1224_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre, S. et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155\u2013165 (1995).","journal-title":"Cell"},{"key":"1224_CR3","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","volume":"28","author":"M Calucho","year":"2018","unstructured":"Calucho, M. et al. Correlation between SMA type and SMN2copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul. Disord. 28, 208\u2013215 (2018).","journal-title":"Neuromuscul. Disord"},{"key":"1224_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0960-8966(91)90051-S","volume":"1","author":"V Dubowitz","year":"1991","unstructured":"Dubowitz, V. Chaos in classification of the spinal muscular atrophies of childhood. Neuromuscul. Disord. 1, 77\u201380 (1991).","journal-title":"Neuromuscul. Disord."},{"key":"1224_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri, E. et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul. Disord. 28, 103\u2013115 (2018).","journal-title":"Neuromuscul. Disord."},{"key":"1224_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","volume":"3","author":"RS Finkel","year":"2018","unstructured":"Finkel, R. S. et al. Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul. Disord. 3,\u00a0197\u2013207 (2018).","journal-title":"Neuromuscul. Disord."},{"key":"1224_CR7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1089\/nat.2017.0665","volume":"27","author":"A Aartsma-Rus","year":"2017","unstructured":"Aartsma-Rus, A. FDA approval of nusinersen for spinal muscular atrophy makes 2016 the year of splice modulating oligonucleotides. Nucleic Acid Ther. 27, 67\u201369 (2017).","journal-title":"Nucleic Acid Ther."},{"key":"1224_CR8","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s40265-020-01410-z","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon, S. Risdiplam: first approval. Drugs 80, 1853\u20131858 (2020).","journal-title":"Drugs"},{"key":"1224_CR9","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","volume":"79","author":"SM Hoy","year":"2019","unstructured":"Hoy, S. M. Onasemnogene abeparvovec: first global approval. Drugs 79, 1255\u20131262 (2019).","journal-title":"Drugs"},{"key":"1224_CR10","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell, J. R. et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N. Engl. J. Med. 377, 1713\u20131722 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1224_CR11","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri, E. et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N. Engl. J. Med. 378, 625\u2013635 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1224_CR12","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel, R. S. et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377, 1723\u20131732 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1224_CR13","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJMoa2009965","volume":"384","author":"G Baranello","year":"2021","unstructured":"Baranello, G. et al. Risdiplam in type 1 spinal muscular atrophy. N. Engl. J. Med. 384, 915\u2013923 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1224_CR14","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2102047","volume":"385","author":"BT Darras","year":"2021","unstructured":"Darras, B. T. et al. Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N. Engl. J. Med. 385, 427\u2013435 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1224_CR15","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1111\/ene.15499","volume":"30","author":"E Mercuri","year":"2023","unstructured":"Mercuri, E. et al. Risdiplam in types 2 and 3 spinal muscular atrophy: a randomised, placebo-controlled, dose-finding trial followed by 24\u2009months of treatment. Eur. J. Neurol. 30, 1945\u20131956 (2023).","journal-title":"Eur. J. Neurol."},{"key":"1224_CR16","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","volume":"20","author":"E Mercuri","year":"2021","unstructured":"Mercuri, E. et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 20, 832\u2013841 (2021).","journal-title":"Lancet Neurol."},{"key":"1224_CR17","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day, J. W. et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2(STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 20, 284\u2013293 (2021).","journal-title":"Lancet Neurol."},{"key":"1224_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","volume":"21","author":"E Mercuri","year":"2022","unstructured":"Mercuri, E. et al. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 21, 42\u201352 (2022).","journal-title":"Lancet Neurol."},{"key":"1224_CR19","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","volume":"83","author":"RS Finkel","year":"2014","unstructured":"Finkel, R. S. et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology 83, 810\u2013817 (2014).","journal-title":"Neurology"},{"key":"1224_CR20","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ana.25101","volume":"82","author":"SJ Kolb","year":"2017","unstructured":"Kolb, S. J. et al. Natural history of infantile-onset spinal muscular atrophy. Ann. Neurol. 82, 883\u2013891 (2017).","journal-title":"Ann. Neurol."},{"key":"1224_CR21","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1111\/ene.15768","volume":"30","author":"M Pane","year":"2023","unstructured":"Pane, M. et al. Type I spinal muscular atrophy patients treated with nusinersen: 4-year follow-up of motor, respiratory and bulbar function. Eur. J. Neurol. 30, 1755\u20131763 (2023).","journal-title":"Eur. J. Neurol."},{"key":"1224_CR22","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"DC De Vivo","year":"2019","unstructured":"De Vivo, D. C. et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul. Disord. 29, 842\u2013856 (2019).","journal-title":"Neuromuscul. Disord."},{"key":"1224_CR23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1056\/NEJMoa2410120","volume":"393","author":"RS Finkel","year":"2025","unstructured":"Finkel, R. S. et al. Risdiplam in presymptomatic spinal muscular atrophy. N. Engl. J. Med. 393, 671\u2013682 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1224_CR24","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss, K. A. et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2at risk for spinal muscular atrophy type 1: the phase III SPR1NT trial. Nat. Med. 28, 1381\u20131389 (2022).","journal-title":"Nat. Med."},{"key":"1224_CR25","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss, K. A. et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2at risk for spinal muscular atrophy: the phase III SPR1NT trial. Nat. Med. 28, 1390\u20131397 (2022).","journal-title":"Nat. Med."},{"key":"1224_CR26","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/mt.2009.15","volume":"17","author":"FP Manfredsson","year":"2009","unstructured":"Manfredsson, F. P., Rising, A. C. & Mandel, R. J. AAV9: a potential blood\u2013brain barrier buster. Mol. Ther. 17, 403\u2013405 (2009).","journal-title":"Mol. Ther."},{"key":"1224_CR27","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41591-025-04103-w","volume":"32","author":"CM Proud","year":"2026","unstructured":"Proud, C. M. et al. Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial. Nat. Med. 32, 481\u2013487 (2026).","journal-title":"Nat. Med."},{"key":"1224_CR28","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41591-025-04119-2","volume":"32","author":"JM Kwon","year":"2026","unstructured":"Kwon, J. M. et al. Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial. Nat. Med. 32, 488\u2013493 (2026).","journal-title":"Nat. Med."},{"key":"1224_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-02065-z","volume":"16","author":"G Coratti","year":"2021","unstructured":"Coratti, G. et al. Motor function in type 2 and 3 SMA patients treated with nusinersen: a critical review and meta-analysis. Orphanet J. Rare Dis. 16, 430 (2021).","journal-title":"Orphanet J. Rare Dis."},{"key":"1224_CR30","doi-asserted-by":"publisher","first-page":"948","DOI":"10.29271\/jcpsp.2024.08.948","volume":"34","author":"B Chen","year":"2024","unstructured":"Chen, B., Gong, Y. & Zhou, T. The impact of nusinersen and risdiplam on motor function for spinal muscular atrophy type 2 and 3: a meta-analysis. J. Coll. Physicians Surg. Pak. 34, 948\u2013955 (2024).","journal-title":"J. Coll. Physicians Surg. Pak."},{"key":"1224_CR31","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1007\/s12325-025-03260-1","volume":"42","author":"T Hagenacker","year":"2025","unstructured":"Hagenacker, T., Paradis, A. D., Lawson-Michod, K. A. & Youn, B. Systematic review and meta-analysis of long-term nusinersen effectiveness in adolescents and adults with spinal muscular atrophy. Adv. Ther. 42, 4143\u20134160 (2025).","journal-title":"Adv. Ther."},{"key":"1224_CR32","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3390\/brainsci13101419","volume":"13","author":"Y Qiao","year":"2023","unstructured":"Qiao, Y., Chi, Y., Gu, J. & Ma, Y. Safety and efficacy of nusinersen and risdiplam for spinal muscular atrophy: a systematic review and meta-analysis of randomized controlled trials. Brain Sci. 13, 1419 (2023).","journal-title":"Brain Sci"},{"key":"1224_CR33","doi-asserted-by":"publisher","first-page":"e0302860","DOI":"10.1371\/journal.pone.0302860","volume":"19","author":"BD Fernandes","year":"2024","unstructured":"Fernandes, B. D. et al. Efficacy and safety of onasemnogene abeparvovec for the treatment of patients with spinal muscular atrophy type 1: a systematic review with meta-analysis. PLoS ONE 19, e0302860 (2024).","journal-title":"PLoS ONE"},{"key":"1224_CR34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/phar.2866","volume":"44","author":"C Pascual-Morena","year":"2024","unstructured":"Pascual-Morena, C. et al. Efficacy of risdiplam in spinal muscular atrophy: a systematic review and meta-analysis. Pharmacotherapy 44, 97\u2013105 (2024).","journal-title":"Pharmacotherapy"},{"key":"1224_CR35","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s12325-024-03101-7","volume":"42","author":"X Zhao","year":"2025","unstructured":"Zhao, X. et al. Motor function and safety of nusinersen and risdiplam in Asian patients with types 2-4 spinal muscular atrophy (SMA): a systematic review and meta-analysis. Adv. Ther. 42, 1611\u20131626 (2025).","journal-title":"Adv. Ther."},{"key":"1224_CR36","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1177\/22143602251385045","volume":"13","author":"SE Matesanz","year":"2026","unstructured":"Matesanz, S. E. & Finkel, R. S. Real-world evidence on nusinersen treatment of persons with SMA: a focused review. J. Neuromuscul. Dis. 13, 190\u2013206 (2026).","journal-title":"J. Neuromuscul. Dis."},{"key":"1224_CR37","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1007\/s00415-021-10954-3","volume":"269","author":"S Bonanno","year":"2022","unstructured":"Bonanno, S. et al. Quality of life assessment in adult spinal muscular atrophy patients treated with nusinersen. J. Neurol. 269, 3264\u20133275 (2022).","journal-title":"J. Neurol."},{"key":"1224_CR38","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1007\/s00415-024-12203-9","volume":"271","author":"S Brakemeier","year":"2024","unstructured":"Brakemeier, S., Lipka, J., Schlag, M., Kleinschnitz, C. & Hagenacker, T. Risdiplam improves subjective swallowing quality in non-ambulatory adult patients with 5q-spinal muscular atrophy despite advanced motor impairment. J. Neurol. 271, 2649\u20132657 (2024).","journal-title":"J. Neurol."},{"key":"1224_CR39","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1212\/CPJ.0000000000001033","volume":"11","author":"T Duong","year":"2021","unstructured":"Duong, T. et al. Nusinersen treatment in adults with spinal muscular atrophy. Neurol. Clin. Pract. 11, e317\u2013e327 (2021).","journal-title":"Neurol. Clin. Pract."},{"key":"1224_CR40","doi-asserted-by":"publisher","first-page":"650535","DOI":"10.3389\/fneur.2021.650535","volume":"12","author":"B Elsheikh","year":"2021","unstructured":"Elsheikh, B. et al. Safety, tolerability, and effect of nusinersen treatment in ambulatory adults with 5q-SMA. Front. Neurol. 12, 650535 (2021).","journal-title":"Front. Neurol."},{"key":"1224_CR41","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1136\/jnnp-2020-324036","volume":"91","author":"MA Farrar","year":"2020","unstructured":"Farrar, M. A. & Kiernan, M. C. Treating adults with spinal muscular atrophy with nusinersen. J. Neurol. Neurosurg. Psychiatry 91, 1139 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1224_CR42","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","volume":"19","author":"T Hagenacker","year":"2020","unstructured":"Hagenacker, T. et al. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol. 19, 317\u2013325 (2020).","journal-title":"Lancet Neurol"},{"key":"1224_CR43","doi-asserted-by":"publisher","first-page":"115230","DOI":"10.1016\/j.expneurol.2025.115230","volume":"389","author":"PF Hsieh","year":"2025","unstructured":"Hsieh, P. F. et al. Mechanisms of functional improvement behind nusinersen treatment in adult spinal muscular atrophy. Exp. Neurol. 389, 115230 (2025).","journal-title":"Exp. Neurol."},{"key":"1224_CR44","doi-asserted-by":"publisher","first-page":"175628642090780","DOI":"10.1177\/1756286420907803","volume":"13","author":"E Jochmann","year":"2020","unstructured":"Jochmann, E. et al. Experiences from treating seven adult 5q spinal muscular atrophy patients with nusinersen. Ther. Adv. Neurol. Disord. 13, 1756286420907803 (2020).","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"1224_CR45","first-page":"1","volume":"25","author":"K Lam","year":"2020","unstructured":"Lam, K. & Wu, A. Clinical outcome of adult spinal muscular atrophy patients treated with nusinersen: a case series review. Perm. J. 25, 1 (2020).","journal-title":"Perm. J."},{"key":"1224_CR46","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S1474-4422(20)30068-5","volume":"19","author":"E Mercuri","year":"2020","unstructured":"Mercuri, E. & Sansone, V. Nusinersen in adults with spinal muscular atrophy: new challenges. Lancet Neurol. 19, 283\u2013284 (2020).","journal-title":"Lancet Neurol."},{"key":"1224_CR47","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/ene.14567","volume":"28","author":"VA Sansone","year":"2021","unstructured":"Sansone, V. A. et al. Sometimes they come back: new and old spinal muscular atrophy adults in the era of nusinersen. Eur. J. Neurol. 28, 602\u2013608\u00a0(2021).","journal-title":"Eur. J. Neurol."},{"key":"1224_CR48","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/acn3.51514","volume":"9","author":"M Pane","year":"2022","unstructured":"Pane, M. et al. Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy. Ann. Clin. Transl. Neurol. 9, 404\u2013409 (2022).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1224_CR49","doi-asserted-by":"publisher","first-page":"101997","DOI":"10.1016\/j.eclinm.2023.101997","volume":"59","author":"M Pane","year":"2023","unstructured":"Pane, M. et al. Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naive patients with spinal muscular atrophy and following switch from other therapies. EClinicalMedicine 59, 101997 (2023).","journal-title":"EClinicalMedicine"},{"key":"1224_CR50","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3233\/JND-230122","volume":"11","author":"L Servais","year":"2024","unstructured":"Servais, L. et al. Real-world outcomes in patients with spinal muscular atrophy treated with onasemnogene abeparvovec monotherapy: findings from the RESTORE registry. J. Neuromuscul. Dis. 11, 425\u2013442 (2024).","journal-title":"J. Neuromuscul. Dis."},{"key":"1224_CR51","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1007\/s40120-025-00791-1","volume":"14","author":"W Toro","year":"2025","unstructured":"Toro, W. et al. Early intervention and speed-to-effect in spinal muscular atrophy type 1 following onasemnogene abeparvovec gene replacement therapy: results of apost-hoc analysis of pooled clinical study data. Neurol. Ther. 14, 1903\u20131918 (2025).","journal-title":"Neurol. Ther."},{"key":"1224_CR52","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2352-4642(21)00287-X","volume":"6","author":"C Weiss","year":"2022","unstructured":"Weiss, C. et al. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24\u2009months or younger and bodyweight up to 15\u2009kg: an observational cohort study. Lancet Child Adolesc. Health 6, 17\u201327 (2022).","journal-title":"Lancet Child Adolesc. Health"},{"key":"1224_CR53","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ana.20473","volume":"57","author":"KJ Swoboda","year":"2005","unstructured":"Swoboda, K. J. et al. Natural history of denervation in SMA: relation to age, SMN2copy number, and function. Ann. Neurol. 57, 704\u2013712 (2005).","journal-title":"Ann. Neurol."},{"key":"1224_CR54","doi-asserted-by":"publisher","first-page":"eabb6871","DOI":"10.1126\/scitranslmed.abb6871","volume":"13","author":"L Kong","year":"2021","unstructured":"Kong, L. et al. Impaired prenatal motor axon development necessitates early therapeutic intervention in severe SMA. Sci. Transl. Med. 13, eabb6871 (2021).","journal-title":"Sci. Transl. Med."},{"key":"1224_CR55","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1172\/JCI124120","volume":"129","author":"DM Ramos","year":"2019","unstructured":"Ramos, D. M. et al. Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment. J. Clin. Invest. 129, 4817\u20134831 (2019).","journal-title":"J. Clin. Invest."},{"key":"1224_CR56","doi-asserted-by":"publisher","first-page":"105454","DOI":"10.1016\/j.nmd.2025.105454","volume":"55","author":"M Chroscinska-Krawczyk","year":"2025","unstructured":"Chroscinska-Krawczyk, M., Koziol, I. & Zienkiewicz, E. Real-world experience with switch to onasemnogene abeparvovec after initial therapy with nusinersen or risdiplam. Neuromuscul. Disord. 55, 105454 (2025).","journal-title":"Neuromuscul. Disord."},{"key":"1224_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03326-3","volume":"19","author":"I Desguerre","year":"2024","unstructured":"Desguerre, I. et al. Real-world multidisciplinary outcomes of onasemnogene abeparvovec monotherapy in patients with spinal muscular atrophy type 1: experience of the French cohort in the first three years of treatment. Orphanet J. Rare Dis. 19, 344 (2024).","journal-title":"Orphanet J. Rare Dis."},{"key":"1224_CR58","doi-asserted-by":"publisher","first-page":"100817","DOI":"10.1016\/j.lanepe.2023.100817","volume":"37","author":"V Gowda","year":"2024","unstructured":"Gowda, V. et al. Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: real-world evidence from 6 infusion centres in the United Kingdom. Lancet Reg. Health Eur. 37, 100817 (2024).","journal-title":"Lancet Reg. Health Eur."},{"key":"1224_CR59","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.nmd.2023.11.010","volume":"34","author":"MA Waldrop","year":"2024","unstructured":"Waldrop, M. A. et al. Continued safety and long-term effectiveness of onasemnogene abeparvovec in Ohio. Neuromuscul. Disord. 34, 41\u201348 (2024).","journal-title":"Neuromuscul. Disord."},{"key":"1224_CR60","doi-asserted-by":"publisher","first-page":"101092","DOI":"10.1016\/j.lanepe.2024.101092","volume":"47","author":"C Weiss","year":"2024","unstructured":"Weiss, C. et al. Efficacy and safety of gene therapy with onasemnogene abeparvovec in children with spinal muscular atrophy in the D-A-CH-region: a population-based observational study. Lancet Reg. Health Eur. 47, 101092 (2024).","journal-title":"Lancet Reg. Health Eur."},{"key":"1224_CR61","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/CND.0000000000000521","volume":"26","author":"S Chelladurai","year":"2025","unstructured":"Chelladurai, S., D\u2019Urso, S., Atherton, M. & Ong, M. T. Safety of onasemnogene abeparvovec administration to type 1 SMA patients who have received risdiplam. J. Clin. Neuromuscul. Dis. 26, 140\u2013147 (2025).","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"1224_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02420-8","volume":"17","author":"A Hahn","year":"2022","unstructured":"Hahn, A. et al. Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany. Orphanet J. Rare Dis. 17, 276 (2022).","journal-title":"Orphanet J. Rare Dis."},{"key":"1224_CR63","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3390\/jpm14030244","volume":"14","author":"A Belancic","year":"2024","unstructured":"Belancic, A., Strbad, T., Kucan Stiglic, M. & Vitezic, D. Switching from nusinersen to risdiplam: a Croatian real-world experience on effectiveness and safety. J. Pers. Med. 14, 244 (2024).","journal-title":"J. Pers. Med."},{"key":"1224_CR64","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/mus.28015","volume":"69","author":"JC Powell","year":"2024","unstructured":"Powell, J. C., Meiling, J. B. & Cartwright, M. S. A case series evaluating patient perceptions after switching from nusinersen to risdiplam for spinal muscular atrophy. Muscle Nerve 69, 179\u2013184 (2024).","journal-title":"Muscle Nerve"},{"key":"1224_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-024-03562-x","volume":"24","author":"B Bjelica","year":"2024","unstructured":"Bjelica, B. et al. Risdiplam therapy in adults with 5q-SMA: observational study on motor function and treatment satisfaction. BMC Neurol. 24, 67 (2024).","journal-title":"BMC Neurol"},{"key":"1224_CR66","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1007\/s10072-025-08125-7","volume":"46","author":"E Albamonte","year":"2025","unstructured":"Albamonte, E. et al. Patients on treatment with risdiplam in Italy: challenges in the interpretation of the real-world data. Neurol. Sci. 46, 3839\u20133849 (2025).","journal-title":"Neurol. Sci."},{"key":"1224_CR67","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/mus.28329","volume":"71","author":"CE Bekircan-Kurt","year":"2025","unstructured":"Bekircan-Kurt, C. E. et al. Transitioning from nusinersen to risdiplam for spinal muscular atrophy in clinical practice: a single-center experience. Muscle Nerve 71, 414\u2013421 (2025).","journal-title":"Muscle Nerve"},{"key":"1224_CR68","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/mus.28327","volume":"71","author":"M Gavriilaki","year":"2025","unstructured":"Gavriilaki, M., Moschou, M., Pagiantza, M., Arnaoutoglou, M. & Kimiskidis, V. Risdiplam in adult patients with 5q spinal muscular atrophy: a single-center longitudinal study. Muscle Nerve 71, 384\u2013391 (2025).","journal-title":"Muscle Nerve"},{"key":"1224_CR69","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/00185787241282213","volume":"60","author":"E Castellana","year":"2025","unstructured":"Castellana, E. Switching from nusinersen to risdiplam in spinal muscular atrophy: a comparative analysis of safety, efficacy, and economic impact. Hosp. Pharm. 60, 103\u2013104 (2025).","journal-title":"Hosp. Pharm."},{"key":"1224_CR70","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1007\/s12325-024-02845-6","volume":"41","author":"C Kokaliaris","year":"2024","unstructured":"Kokaliaris, C. et al. Long-term comparative efficacy and safety of risdiplam and nusinersen in children with type 1 spinal muscular atrophy. Adv. Ther. 41, 2414\u20132434 (2024).","journal-title":"Adv. Ther."},{"key":"1224_CR71","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2217\/cer-2021-0216","volume":"11","author":"VA Ribero","year":"2022","unstructured":"Ribero, V. A. et al. How does risdiplam compare with other treatments for types 1\u20133 spinal muscular atrophy: a systematic literature review and indirect treatment comparison. J. Comp. Eff. Res. 11, 347\u2013370 (2022).","journal-title":"J. Comp. Eff. Res."},{"key":"1224_CR72","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1080\/03007995.2021.1947216","volume":"37","author":"M Bischof","year":"2021","unstructured":"Bischof, M. et al. Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1. Curr. Med. Res. Opin. 37, 1719\u20131730 (2021).","journal-title":"Curr. Med. Res. Opin."},{"key":"1224_CR73","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1007\/s12325-019-00923-8","volume":"36","author":"O Dabbous","year":"2019","unstructured":"Dabbous, O. et al. Survival, motor function, and motor milestones: comparison of AVXS-101 relative to nusinersen for the treatment of infants with spinal muscular atrophy type 1. Adv. Ther. 36, 1164\u20131176 (2019).","journal-title":"Adv. Ther."},{"key":"1224_CR74","doi-asserted-by":"publisher","first-page":"106210","DOI":"10.1016\/j.nmd.2025.106210","volume":"54","author":"M Barzegar","year":"2025","unstructured":"Barzegar, M. et al. Risdiplam and nusinersen in spinal muscular atrophy: a descriptive real-world study on motor function outcomes in northwestern Iran. Neuromuscul. Disord. 54, 106210 (2025).","journal-title":"Neuromuscul. Disord."},{"key":"1224_CR75","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00415-025-13589-w","volume":"273","author":"S Neuhoff","year":"2026","unstructured":"Neuhoff, S. et al. Matched-pair analysis of motor outcomes in adults with spinal muscular atrophy on nusinersen vs. risdiplam. J. Neurol. 273, 55 (2026).","journal-title":"J. Neurol."},{"key":"1224_CR76","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1177\/22143602251387019","volume":"13","author":"C Weiss","year":"2026","unstructured":"Weiss, C. et al. Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland\u2014part I\u2014systematic literature review and existing evidence. J. Neuromuscul. Dis. 13, 420\u2013435 (2026).","journal-title":"J. Neuromuscul. Dis."},{"key":"1224_CR77","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","volume":"78","author":"JR Mendell","year":"2021","unstructured":"Mendell, J. R. et al. Five-year extension results of the phase 1 start trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol. 78, 834\u2013841 (2021).","journal-title":"JAMA Neurol."},{"key":"1224_CR78","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41434-025-00535-8","volume":"32","author":"P Pongsakornkullachart","year":"2025","unstructured":"Pongsakornkullachart, P. et al. Fatal outcomes following onasemnogene abeparvovec in advanced-stage spinal muscular atrophy. Gene Ther. 32, 553\u2013560 (2025).","journal-title":"Gene Ther."},{"key":"1224_CR79","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ejpn.2024.09.009","volume":"53","author":"M Wik-Klokk","year":"2024","unstructured":"Wik-Klokk, M. et al. Type 1 spinal muscular atrophy treated with nusinersen in Norway, a five-year follow-up. Eur. J. Paediatr. Neurol. 53, 109\u2013116 (2024).","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"1224_CR80","doi-asserted-by":"publisher","first-page":"702","DOI":"10.55730\/1300-0144.6018","volume":"55","author":"MA Kilic","year":"2025","unstructured":"Kilic, M. A. et al. The long-term efficacy of nusinersen on respiratory functions in children with symptomatic spinal muscular atrophy type 1. Turk. J. Med. Sci. 55, 702\u2013709 (2025).","journal-title":"Turk. J. Med. Sci."},{"key":"1224_CR81","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1017\/cjn.2025.74","volume":"53","author":"G Gauvreau","year":"2026","unstructured":"Gauvreau, G. et al. Respiratory and bulbar support in spinal muscular atrophy type I treated with nusinersen. Can. J. Neurol. Sci. 53, 44\u201351 (2026).","journal-title":"Can. J. Neurol. Sci."},{"key":"1224_CR82","doi-asserted-by":"publisher","first-page":"108983","DOI":"10.1016\/j.clineuro.2025.108983","volume":"255","author":"A Tscherter","year":"2025","unstructured":"Tscherter, A. et al. Real-world data on the effect of long-term treatment with nusinersen over >4\u2009years in a cohort of Swiss patients with spinal muscular atrophy. Clin. Neurol. Neurosurg. 255, 108983 (2025).","journal-title":"Clin. Neurol. Neurosurg."},{"key":"1224_CR83","unstructured":"Finkel, R. et al. Final safety and efficacy data from the SHINE study in participants with infantile-onset and later-onset SMA. In Annual Cure SMA Research and Clinical Care Meeting https:\/\/www.biogenconferences.com\/CureSMA2024\/CureSMA2024_Finkel_SHINE_safety_efficacy_Poster.pdf (2026)."},{"key":"1224_CR84","unstructured":"Servais, L. et al. SUNFISH parts 1 and 2: 5-year efficacy and safety data of risdiplam in types 2 and 3 spinal muscular atrophy. In MDA Conf. (2026)."},{"key":"1224_CR85","doi-asserted-by":"publisher","first-page":"4735","DOI":"10.1007\/s00431-024-05735-9","volume":"183","author":"M Pane","year":"2024","unstructured":"Pane, M. et al. Prognostic factors for tube feeding in type I SMA patients treated with disease-modifying therapies: a cohort study. Eur. J. Pediatr. 183, 4735\u20134745 (2024).","journal-title":"Eur. J. Pediatr."},{"key":"1224_CR86","doi-asserted-by":"publisher","first-page":"e70268","DOI":"10.1111\/ene.70268","volume":"32","author":"G Coratti","year":"2025","unstructured":"Coratti, G. et al. Longitudinal assessment of 4-year HFMSE changes in SMA II and III patients treated with nusinersen. Eur. J. Neurol. 32, e70268 (2025).","journal-title":"Eur. J. Neurol."},{"key":"1224_CR87","doi-asserted-by":"publisher","first-page":"100862","DOI":"10.1016\/j.lanepe.2024.100862","volume":"39","author":"R Gunther","year":"2024","unstructured":"Gunther, R. et al. Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study. Lancet Reg. Health Eur. 39, 100862 (2024).","journal-title":"Lancet Reg. Health Eur."},{"key":"1224_CR88","doi-asserted-by":"publisher","first-page":"103536","DOI":"10.1016\/j.eclinm.2025.103536","volume":"88","author":"O Keritam","year":"2025","unstructured":"Keritam, O. et al. Efficacy and safety of risdiplam in adults with 5q-associated spinal muscular atrophy: a nationwide observational cohort study in Austria. EClinicalMedicine 88, 103536 (2025).","journal-title":"EClinicalMedicine"},{"key":"1224_CR89","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.nmd.2024.02.003","volume":"38","author":"K McGrattan","year":"2024","unstructured":"McGrattan, K., Conway, E., Cerchiari, A., Berti, B. & Fanelli, L. Bulbar function in spinal muscular atrophy (SMA): state of art and new challenges. Neuromuscul. Disord.\u00a038, 44-50\u00a0(2024).","journal-title":"Neuromuscul. Disord."},{"key":"1224_CR90","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1044\/2021_AJSLP-20-00217","volume":"30","author":"KE McGrattan","year":"2021","unstructured":"McGrattan, K. E., Graham, R. J., DiDonato, C. J. & Darras, B. T. Dysphagia phenotypes in spinal muscular atrophy: the past, present, and promise for the future. Am. J. Speech Lang. Pathol. 30, 1008\u20131022 (2021).","journal-title":"Am. J. Speech Lang. Pathol."},{"key":"1224_CR91","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3233\/JND-221531","volume":"10","author":"KE McGrattan","year":"2023","unstructured":"McGrattan, K. E. et al. Patients with spinal muscular atrophy type 1 achieve and maintain bulbar function following onasemnogene abeparvovec treatment. J. Neuromuscul. Dis. 10, 531\u2013540 (2023).","journal-title":"J. Neuromuscul. Dis."},{"key":"1224_CR92","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/brain\/awac252","volume":"146","author":"A Pechmann","year":"2023","unstructured":"Pechmann, A. et al. Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy. Brain 146, 668\u2013677 (2023).","journal-title":"Brain"},{"key":"1224_CR93","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1111\/dmcn.16387","volume":"67","author":"G Stimpson","year":"2025","unstructured":"Stimpson, G. et al. Bulbar function in children with spinal muscular atrophy type 1 treated with nusinersen. Dev. Med. Child Neurol.\u00a067,\u00a01590\u20131600\u00a0(2025).","journal-title":"Dev. Med. Child Neurol."},{"key":"1224_CR94","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/dmcn.15171","volume":"64","author":"H Weststrate","year":"2022","unstructured":"Weststrate, H. et al. Evolution of bulbar function in spinal muscular atrophy type 1 treated with nusinersen. Dev. Med. Child Neurol. 64, 907\u2013914 (2022).","journal-title":"Dev. Med. Child Neurol."},{"key":"1224_CR95","doi-asserted-by":"publisher","first-page":"e587","DOI":"10.1212\/WNL.0000000000011051","volume":"96","author":"F Trucco","year":"2021","unstructured":"Trucco, F. et al. Respiratory trajectories in type 2 and 3 spinal muscular atrophy in the iSMAC cohort study. Neurology 96, e587\u2013e599 (2021).","journal-title":"Neurology"},{"key":"1224_CR96","doi-asserted-by":"publisher","first-page":"e200298","DOI":"10.1212\/CPJ.0000000000200298","volume":"14","author":"F Trucco","year":"2024","unstructured":"Trucco, F. et al. Therapeutic role of nusinersen on respiratory progression in pediatric patients with spinal muscular atrophy type 2 and nonambulant type 3. Neurol. Clin. Pract. 14, e200298 (2024).","journal-title":"Neurol. Clin. Pract"},{"key":"1224_CR97","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1002\/acn3.51889","volume":"10","author":"CM Proud","year":"2023","unstructured":"Proud, C. M. et al. Combination disease-modifying treatment in spinal muscular atrophy: a proposed classification. Ann. Clin. Transl. Neurol. 10, 2155\u20132160 (2023).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1224_CR98","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel, R. S. et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 388, 3017\u20133026 (2016).","journal-title":"Lancet"},{"key":"1224_CR99","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41591-021-01483-7","volume":"27","author":"G Thomsen","year":"2021","unstructured":"Thomsen, G. et al. Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue. Nat. Med. 27, 1701\u20131711 (2021).","journal-title":"Nat. Med."},{"key":"1224_CR100","doi-asserted-by":"publisher","first-page":"e193956","DOI":"10.1172\/JCI193956","volume":"135","author":"CM Proud","year":"2025","unstructured":"Proud, C. M. et al. Open-label phase 4 trial evaluating nusinersen after onasemnogene abeparvovec in children with spinal muscular atrophy. J. Clin. Invest. 135, e193956 (2025).","journal-title":"J. Clin. Invest."},{"key":"1224_CR101","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-025-04276-4","volume":"25","author":"MD Svoboda","year":"2025","unstructured":"Svoboda, M. D. et al. Risdiplam treatment following onasemnogene abeparvovec in individuals with spinal muscular atrophy: a multicenter case series. BMC Neurol. 25, 283 (2025).","journal-title":"BMC Neurol."},{"key":"1224_CR102","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/s41591-025-04193-6","volume":"32","author":"RS Finkel","year":"2026","unstructured":"Finkel, R. S. et al. High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial. Nat. Med. 32, 1095\u20131104 (2026).","journal-title":"Nat. Med."},{"key":"1224_CR103","doi-asserted-by":"publisher","first-page":"e210268","DOI":"10.1212\/WNL.0000000000210268","volume":"104","author":"HJ McMillan","year":"2025","unstructured":"McMillan, H. J. et al. Safety and efficacy of IV onasemnogene abeparvovec for pediatric patients with spinal muscular atrophy: the phase 3b smart study. Neurology 104, e210268 (2025).","journal-title":"Neurology"},{"key":"1224_CR104","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3233\/JND-221560","volume":"10","author":"RS Finkel","year":"2023","unstructured":"Finkel, R. S. et al. Intrathecal onasemnogene abeparvovec for sitting, nonambulatory patients with spinal muscular atrophy: phase I ascending-dose study (STRONG). J. Neuromuscul. Dis. 10, 389\u2013404 (2023).","journal-title":"J. Neuromuscul. Dis."},{"key":"1224_CR105","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1089\/hum.2021.255","volume":"33","author":"FF Tukov","year":"2022","unstructured":"Tukov, F. F. et al. Single-dose intrathecal dorsal root ganglia toxicity of onasemnogene abeparvovec in cynomolgus monkeys. Hum. Gene Ther. 33, 740\u2013756 (2022).","journal-title":"Hum. Gene Ther."},{"key":"1224_CR106","doi-asserted-by":"publisher","unstructured":"Lock Hock Ngu, Q. M. et al. Safety and efficacy of vesemnogene lantuparvovec, an AAV-based gene therapy in young children under 24 months with spinal muscular atrophy in low- and-middle-income countries. Second interim report. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2025.04.13.25325764 (2025).","DOI":"10.1101\/2025.04.13.25325764"},{"key":"1224_CR107","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.nmd.2020.07.004","volume":"30","author":"G Coratti","year":"2020","unstructured":"Coratti, G. et al. Gain and loss of abilities in type II SMA: a 12-month natural history study. Neuromusc. Disord. 30, 765\u2013771 (2020).","journal-title":"Neuromusc. Disord."},{"key":"1224_CR108","doi-asserted-by":"publisher","first-page":"e0267930","DOI":"10.1371\/journal.pone.0267930","volume":"17","author":"G Coratti","year":"2022","unstructured":"Coratti, G. et al. Predictive models in SMA II natural history trajectories using machine learning: a proof of concept study. PLoS ONE 17, e0267930 (2022).","journal-title":"PLoS ONE"},{"key":"1224_CR109","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.nmd.2021.03.012","volume":"31","author":"G Coratti","year":"2021","unstructured":"Coratti, G. et al. Age related treatment effect in type II spinal muscular atrophy pediatric patients treated with nusinersen. Neuromuscul. Disord. 31, 596\u2013602 (2021).","journal-title":"Neuromuscul. Disord."},{"key":"1224_CR110","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.nmd.2020.07.004","volume":"30","author":"G Coratti","year":"2020","unstructured":"Coratti, G. et al. Gain and loss of abilities in type II SMA: a 12-month natural history study. Neuromuscul. Disord. 30, 765\u2013771 (2020).","journal-title":"Neuromuscul. Disord."},{"key":"1224_CR111","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1002\/ana.25900","volume":"88","author":"G Coratti","year":"2020","unstructured":"Coratti, G. et al. Clinical variability in spinal muscular atrophy type III. Ann. Neurol. 88, 1109\u20131117 (2020).","journal-title":"Ann. Neurol."},{"key":"1224_CR112","first-page":"221436022513951","volume":"11","author":"Y Erbas","year":"2025","unstructured":"Erbas, Y. et al. Trach and treat: safety and motor outcomes following onasemnogene abeparvovec in patients with spinal muscular atrophy and tracheostomies in the RESTORE registry. J. Neuromuscul. Dis. 11, 22143602251395173 (2025).","journal-title":"J. Neuromuscul. Dis."},{"key":"1224_CR113","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.nmd.2020.07.005","volume":"30","author":"G Coratti","year":"2020","unstructured":"Coratti, G. et al. Age and baseline values predict 12 and 24-month functional changes in type 2 SMA. Neuromuscul. Disord. 30, 756\u2013764 (2020).","journal-title":"Neuromuscul. Disord."},{"key":"1224_CR114","doi-asserted-by":"publisher","first-page":"e70023","DOI":"10.1002\/bimj.70023","volume":"67","author":"M Hackenberg","year":"2025","unstructured":"Hackenberg, M. et al. Investigating a domain adaptation approach for integrating different measurement instruments in a longitudinal clinical registry. Biom. J. 67, e70023 (2025).","journal-title":"Biom. J."},{"key":"1224_CR115","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.nmd.2021.10.009","volume":"32","author":"G Coratti","year":"2022","unstructured":"Coratti, G. et al. Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes. Neuromuscul. Disord.\u00a032,\u00a036\u201342 (2022).","journal-title":"Neuromuscul. Disord."},{"key":"1224_CR116","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","volume":"20","author":"AM Glanzman","year":"2010","unstructured":"Glanzman, A. M. et al. The Children\u2019s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability. Neuromuscul. Disord. 20, 155\u2013161 (2010).","journal-title":"Neuromuscul. Disord."},{"key":"1224_CR117","doi-asserted-by":"publisher","first-page":"e0201004","DOI":"10.1371\/journal.pone.0201004","volume":"13","author":"A Chabanon","year":"2018","unstructured":"Chabanon, A. et al. Prospective and longitudinal natural history study of patients with type 2 and 3 spinal muscular atrophy: baseline data NatHis-SMA study. PLoS ONE 13, e0201004 (2018).","journal-title":"PLoS ONE"},{"key":"1224_CR118","doi-asserted-by":"publisher","first-page":"e213839","DOI":"10.1212\/WNL.0000000000213839","volume":"105","author":"A Pasternak","year":"2025","unstructured":"Pasternak, A. et al. Spinal muscular atrophy functional composite score revised (SMA-FCR) in untreated and nusinersen-treated patient cohorts. Neurology 105, e213839 (2025).","journal-title":"Neurology"},{"key":"1224_CR119","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1113\/JP282249","volume":"600","author":"DST Kariyawasam","year":"2022","unstructured":"Kariyawasam, D. S. T. et al. Axonal excitability changes in children with spinal muscular atrophy treated with nusinersen. J. Physiol. 600, 95\u2013109 (2022).","journal-title":"J. Physiol."},{"key":"1224_CR120","doi-asserted-by":"publisher","first-page":"e193956","DOI":"10.1172\/JCI193956","volume":"135","author":"CM Proud","year":"2025","unstructured":"Proud, C. M. et al. Open-label phase IV trial evaluating nusinersen after onasemnogene abeparvovec in children with spinal muscular atrophy. J. Clin. Invest. 135, e193956 (2025).","journal-title":"J. Clin. Invest."},{"key":"1224_CR121","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/mus.70156","volume":"73","author":"R Sun","year":"2026","unstructured":"Sun, R. et al. Electrophysiological changes in pediatric spinal muscular atrophy: results from an observational study. Muscle Nerve\u00a073,\u00a0755\u2013764\u00a0(2026).","journal-title":"Muscle Nerve"},{"key":"1224_CR122","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/jmri.20804","volume":"25","author":"E Mercuri","year":"2007","unstructured":"Mercuri, E. et al. Muscle MRI in inherited neuromuscular disorders: past, present, and future. J. Magn. Reson. Imaging 25, 433\u2013440 (2007).","journal-title":"J. Magn. Reson. Imaging"},{"key":"1224_CR123","first-page":"189","volume":"37","author":"E Zych-Twardowska","year":"2003","unstructured":"Zych-Twardowska, E., Wajgt, A., Lubos, L. & Matusik, E. Parkinsonism\u2013ALS\u2013dementia complex: case report [Polish]. Neurol. Neurochir. Pol. 37, 189\u2013196 (2003).","journal-title":"Neurol. Neurochir. Pol."},{"key":"1224_CR124","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s00415-019-09646-w","volume":"267","author":"C Brogna","year":"2020","unstructured":"Brogna, C. et al. MRI patterns of muscle involvement in type 2 and 3 spinal muscular atrophy patients. J. Neurol. 267, 898\u2013912 (2020).","journal-title":"J. Neurol."},{"key":"1224_CR125","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.crad.2024.06.004","volume":"79","author":"Y Huang","year":"2024","unstructured":"Huang, Y., Chen, T., Hu, Y. & Li, Z. Muscular MRI and magnetic resonance neurography in spinal muscular atrophy. Clin. Radiol. 79, 673\u2013680 (2024).","journal-title":"Clin. Radiol."},{"key":"1224_CR126","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3233\/JND-221671","volume":"11","author":"LAM Otto","year":"2024","unstructured":"Otto, L. A. M. et al. Monitoring nusinersen treatment effects in children with spinal muscular atrophy with quantitative muscle MRI. J. Neuromuscul. Dis. 11, 91\u2013101 (2024).","journal-title":"J. Neuromuscul. Dis."},{"key":"1224_CR127","doi-asserted-by":"publisher","first-page":"e4473","DOI":"10.1002\/nbm.4473","volume":"34","author":"LAM Otto","year":"2021","unstructured":"Otto, L. A. M. et al. Quantification of disease progression in spinal muscular atrophy with muscle MRI\u2014a pilot study. NMR Biomed. 34, e4473 (2021).","journal-title":"NMR Biomed."},{"key":"1224_CR128","doi-asserted-by":"publisher","first-page":"e4357","DOI":"10.1002\/nbm.4357","volume":"33","author":"LAM Otto","year":"2020","unstructured":"Otto, L. A. M. et al. Quantitative MRI of skeletal muscle in a cross-sectional cohort of patients with spinal muscular atrophy types 2 and 3. NMR Biomed. 33, e4357 (2020).","journal-title":"NMR Biomed"},{"key":"1224_CR129","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.nmd.2019.09.002","volume":"29","author":"C Brogna","year":"2019","unstructured":"Brogna, C. et al. Predominant distal muscle involvement in spinal muscular atrophy. Neuromuscul. Disord. 29, 910\u2013911 (2019).","journal-title":"Neuromuscul. Disord."},{"key":"1224_CR130","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.ultrasmedbio.2023.02.021","volume":"49","author":"AL Moreira","year":"2023","unstructured":"Moreira, A. L. et al. Muscle ultrasound changes correlate with functional impairment in spinal muscular atrophy. Ultrasound Med. Biol. 49, 1569\u20131574 (2023).","journal-title":"Ultrasound Med. Biol."},{"key":"1224_CR131","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1093\/brain\/awab411","volume":"145","author":"LE Habets","year":"2022","unstructured":"Habets, L. E. et al. Magnetic resonance reveals mitochondrial dysfunction and muscle remodelling in spinal muscular atrophy. Brain 145, 1422\u20131435 (2022).","journal-title":"Brain"},{"key":"1224_CR132","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/acn3.779","volume":"6","author":"BT Darras","year":"2019","unstructured":"Darras, B. T. et al. Neurofilament as a potential biomarker for spinal muscular atrophy. Ann. Clin. Transl. Neurol. 6, 932\u2013944 (2019).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1224_CR133","first-page":"1170","volume":"12","author":"I Pitarch-Castellano","year":"2025","unstructured":"Pitarch-Castellano, I. et al. Neurofilaments as biomarkers of the efficacy of risdiplam treatment in early SMA phenotypes diagnosed by newborn screening. Children (Basel) 12, 1170 (2025).","journal-title":"Children (Basel)"},{"key":"1224_CR134","doi-asserted-by":"publisher","first-page":"1269406","DOI":"10.3389\/fneur.2023.1269406","volume":"14","author":"M Flotats-Bastardas","year":"2023","unstructured":"Flotats-Bastardas, M. et al. Paradoxical increase of neurofilaments in SMA patients treated with onasemnogene abeparvovec-xioi. Front. Neurol. 14, 1269406 (2023).","journal-title":"Front. Neurol."},{"key":"1224_CR135","doi-asserted-by":"publisher","first-page":"e213371","DOI":"10.1212\/WNL.0000000000213371","volume":"104","author":"I Cordts","year":"2025","unstructured":"Cordts, I. et al. Long-term dynamics of CSF and serum neurofilament light chain in adult patients with 5q spinal muscular atrophy treated with nusinersen. Neurology 104, e213371 (2025).","journal-title":"Neurology"},{"key":"1224_CR136","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/acn3.51355","volume":"8","author":"A Gauthier","year":"2021","unstructured":"Gauthier, A. et al. Comparison of Simoa\u2122 and Ella\u2122 to assess serum neurofilament-light chain in multiple sclerosis. Ann. Clin. Transl. Neurol. 8, 1141\u20131150 (2021).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1224_CR137","doi-asserted-by":"publisher","first-page":"12361","DOI":"10.3390\/ijms232012361","volume":"23","author":"M Notzel","year":"2022","unstructured":"Notzel, M., Werder, L. I., Ziemssen, T. & Akgun, K. Ella versus Simoa serum neurofilament assessment to monitor treatment response in highly active multiple sclerosis patients. Int. J. Mol. Sci. 23, 12361 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1224_CR138","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-29704-8","volume":"13","author":"M Truffi","year":"2023","unstructured":"Truffi, M. et al. Neurofilament-light chain quantification by Simoa and Ella in plasma from patients with dementia: a comparative study. Sci. Rep. 13, 4041 (2023).","journal-title":"Sci. Rep."},{"key":"1224_CR139","doi-asserted-by":"publisher","first-page":"105412","DOI":"10.1016\/j.msard.2023.105412","volume":"82","author":"D Vecchio","year":"2024","unstructured":"Vecchio, D. et al. Serum and cerebrospinal fluid neurofilament light chains measured by SIMOA, Ella, and Lumipulse in multiple sclerosis naive patients. Mult. Scler. Relat. Disord. 82, 105412 (2024).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1224_CR140","doi-asserted-by":"publisher","first-page":"e70215","DOI":"10.1111\/ene.70215","volume":"32","author":"G Primiano","year":"2025","unstructured":"Primiano, G. et al. Comparative analysis of SiMoA and Ella immunoassay platforms for measuring serum neurofilament light chain levels in ATTRv with polyneuropathy and presymptomatic carriers. Eur. J. Neurol. 32, e70215 (2025).","journal-title":"Eur. J. Neurol."},{"key":"1224_CR141","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1097\/WCO.0000000000000853","volume":"33","author":"KR Wagner","year":"2020","unstructured":"Wagner, K. R. The elusive promise of myostatin inhibition for muscular dystrophy. Curr. Opin. Neurol. 33, 621\u2013628 (2020).","journal-title":"Curr. Opin. Neurol."},{"key":"1224_CR142","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s11010-024-05120-y","volume":"480","author":"B Wetzlich","year":"2025","unstructured":"Wetzlich, B., Nyakundi, B. B. & Yang, J. Therapeutic applications and challenges in myostatin inhibition for enhanced skeletal muscle mass and functions. Mol. Cell. Biochem. 480, 1535\u20131553 (2025).","journal-title":"Mol. Cell. Biochem."},{"key":"1224_CR143","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01486-4","volume":"8","author":"V Mariot","year":"2017","unstructured":"Mariot, V. et al. Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches. Nat. Commun. 8, 1859 (2017).","journal-title":"Nat. Commun."},{"key":"1224_CR144","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/jcsm.12542","volume":"11","author":"H Zhou","year":"2020","unstructured":"Zhou, H. et al. Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy. J. Cachexia Sarcopenia Muscle 11, 768\u2013782 (2020).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"1224_CR145","doi-asserted-by":"publisher","first-page":"8763","DOI":"10.3390\/ijms25168763","volume":"25","author":"L Mackels","year":"2024","unstructured":"Mackels, L., Mariot, V., Buscemi, L., Servais, L. & Dumonceaux, J. Impact of disease severity and disease-modifying therapies on myostatin levels in SMA patients. Int. J. Mol. Sci. 25, 8763 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1224_CR146","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1002\/acn3.70070","volume":"12","author":"F Piemonte","year":"2025","unstructured":"Piemonte, F. et al. Myostatin levels in SMA following disease-modifying treatments: a multi-center study. Ann. Clin. Transl. Neurol. 12, 1368\u20131377 (2025).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1224_CR147","doi-asserted-by":"publisher","first-page":"fcae062","DOI":"10.1093\/braincomms\/fcae062","volume":"6","author":"ALA de Albuquerque","year":"2024","unstructured":"de Albuquerque, A. L. A. et al. Serum myostatin as a candidate disease severity and progression biomarker of spinal muscular atrophy. Brain Commun. 6, fcae062 (2024).","journal-title":"Brain Commun."},{"key":"1224_CR148","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.1007\/s12035-024-04605-7","volume":"62","author":"M Guerra","year":"2025","unstructured":"Guerra, M. et al. High expression of SMN circ4-2b-3 in SMA I children treated with nusinersen is associated with improved motor outcomes. Mol. Neurobiol. 62, 5640\u20135649 (2025).","journal-title":"Mol. Neurobiol."},{"key":"1224_CR149","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/acn3.51579","volume":"9","author":"IT Zaharieva","year":"2022","unstructured":"Zaharieva, I. T. et al. Response of plasma microRNAs to nusinersen treatment in patients with SMA. Ann. Clin. Transl. Neurol. 9, 1011\u20131026 (2022).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1224_CR150","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-74338-z","volume":"14","author":"Q Zhang","year":"2024","unstructured":"Zhang, Q. et al. Profiling neuroinflammatory markers and response to nusinersen in paediatric spinal muscular atrophy. Sci. Rep. 14, 23491 (2024).","journal-title":"Sci. Rep."},{"key":"1224_CR151","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/neurolint17080114","volume":"17","author":"A Sipos","year":"2025","unstructured":"Sipos, A. et al. Elevated urinary titin in adult spinal muscular atrophy: a multicenter, cross-sectional observational study. Neurol. Int. 17, 114 (2025).","journal-title":"Neurol. Int."},{"key":"1224_CR152","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41434-025-00513-0","volume":"33","author":"DC Pant","year":"2026","unstructured":"Pant, D. C. & Verma, S. Identifying novel response markers for spinal muscular atrophy revealed by targeted proteomics following gene therapy. Gene Ther. 33, 211\u2013217 (2026).","journal-title":"Gene Ther."},{"key":"1224_CR153","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/s42003-023-05543-1","volume":"6","author":"V Valsecchi","year":"2023","unstructured":"Valsecchi, V. et al. SMN deficiency perturbs monoamine neurotransmitter metabolism in spinal muscular atrophy. Commun. Biol. 6, 1155 (2023).","journal-title":"Commun. Biol."},{"key":"1224_CR154","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1093\/brain\/awac125","volume":"145","author":"RS Finkel","year":"2022","unstructured":"Finkel, R. S. & Benatar, M. Pre-symptomatic spinal muscular atrophy: a proposed nosology. Brain 145, 2247\u20132249 (2022).","journal-title":"Brain"},{"key":"1224_CR155","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1007\/s00431-024-05546-y","volume":"183","author":"M Pane","year":"2024","unstructured":"Pane, M. et al. Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? Eur. J. Pediatr. 183, 2995\u20132999 (2024).","journal-title":"Eur. J. Pediatr."},{"key":"1224_CR156","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1007\/s00431-022-04470-3","volume":"81","author":"MD Pane","year":"2022","unstructured":"Pane, M. D. et al. Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening. Eur. J. Pediatr. 81, 2821\u20132829 (2022).","journal-title":"Eur. J. Pediatr."},{"key":"1224_CR157","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1136\/jmg-2022-108873","volume":"60","author":"E Abiusi","year":"2023","unstructured":"Abiusi, E. et al. Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: towards specific guidelines and standard operating procedures for the molecular diagnosis. J. Med. Genet. 60, 697\u2013705 (2023).","journal-title":"J. Med. Genet."},{"key":"1224_CR158","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1177\/22143602241288095","volume":"11","author":"E Vr\u0161\u010daj","year":"2024","unstructured":"Vr\u0161\u010daj, E., Dangouloff, T., Osredkar, D. & Servais, L. Newborn screening programs for spinal muscular atrophy worldwide in 2023. J. Neuromuscul. Dis. 11, 1180\u20131189 (2024).","journal-title":"J. Neuromuscul. Dis."},{"key":"1224_CR159","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1093\/brain\/awaf123","volume":"148","author":"EF Tizzano","year":"2025","unstructured":"Tizzano, E. F., Lindner, G., Chilcott, E., Finkel, R. S. & Yanez-Munoz, R. J. In utero therapy for spinal muscular atrophy: closer to clinical translation. Brain 148, 3043\u20133056 (2025).","journal-title":"Brain"},{"key":"1224_CR160","doi-asserted-by":"publisher","first-page":"eadv4656","DOI":"10.1126\/scitranslmed.adv4656","volume":"17","author":"B Borges","year":"2025","unstructured":"Borges, B. et al. Intra-amniotic antisense oligonucleotide treatment improves phenotypes in preclinical models of spinal muscular atrophy. Sci. Transl. Med. 17, eadv4656 (2025).","journal-title":"Sci. Transl. Med."},{"key":"1224_CR161","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41434-021-00305-2","volume":"29","author":"KA Rich","year":"2022","unstructured":"Rich, K. A. et al. Premature delivery in the domestic sow in response to in utero delivery of AAV9 to fetal piglets. Gene Ther. 29, 513\u2013519 (2022).","journal-title":"Gene Ther."},{"key":"1224_CR162","doi-asserted-by":"publisher","first-page":"101263","DOI":"10.1016\/j.omtm.2024.101263","volume":"32","author":"B Borges","year":"2024","unstructured":"Borges, B. et al. Prenatal AAV9-GFP administration in fetal lambs results in transduction of female germ cells and maternal exposure to virus. Mol. Ther. Methods Clin. Dev. 32, 101263 (2024).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1224_CR163","unstructured":"Center for Drug Evaluation and Research. Risdiplam pharmacology\/toxicology NDA review and evaluation. FDA https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/213535Orig1s000PharmR.pdf (2019)."},{"key":"1224_CR164","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1056\/NEJMc2300802","volume":"392","author":"RS Finkel","year":"2025","unstructured":"Finkel, R. S. et al. Risdiplam for prenatal therapy of spinal muscular atrophy. N. Engl. J. Med. 392, 1138\u20131140 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1224_CR165","first-page":"1201673","volume":"34","author":"T Dangouloff","year":"2026","unstructured":"Dangouloff, T. et al. Elective preterm birth for earlier spinal muscular atrophy treatment. Case Report 34, 1201673 (2026).","journal-title":"Case Report"},{"key":"1224_CR166","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1007\/s00586-024-08586-y","volume":"34","author":"TL Vu-Han","year":"2025","unstructured":"Vu-Han, T. L. et al. Scoliosis development in 5q-spinal muscular atrophy under disease modifying therapies. Eur. Spine J. 34, 546\u2013555 (2025).","journal-title":"Eur. Spine J."},{"key":"1224_CR167","doi-asserted-by":"publisher","first-page":"104451","DOI":"10.1016\/j.nmd.2024.104451","volume":"44","author":"A Wolfe","year":"2024","unstructured":"Wolfe, A. et al. Spinal presentations in children with spinal muscular atrophy type 1 following gene therapy treatment with onasemnogene abeparvovec\u2014the SMA REACH UK network experience. Neuromuscul. Disord. 44, 104451 (2024).","journal-title":"Neuromuscul. Disord."},{"key":"1224_CR168","doi-asserted-by":"publisher","first-page":"105278","DOI":"10.1016\/j.nmd.2025.105278","volume":"48","author":"S Corti","year":"2025","unstructured":"Corti, S. et al. Italian survey on evolving SMA care with disease-modifying therapies: a consensus workshop on nutrition, swallowing, respiratory and rehabilitation care. Neuromuscul. Disord. 48, 105278 (2025).","journal-title":"Neuromuscul. Disord."},{"key":"1224_CR169","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1136\/jnnp-2023-332084","volume":"95","author":"G Coratti","year":"2024","unstructured":"Coratti, G. et al. Early treatment of type II SMA slows rate of progression of scoliosis. J. Neurol. Neurosurg. Psychiatry 95, 235\u2013240 (2024).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1224_CR170","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.nmd.2022.11.004","volume":"32","author":"G Coratti","year":"2022","unstructured":"Coratti, G. et al. Long term follow-up of scoliosis progression in type II SMA patients. Neuromuscul. Disord. 32, 879\u2013885 (2022).","journal-title":"Neuromuscul. Disord."},{"key":"1224_CR171","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ejpn.2023.11.006","volume":"48","author":"G Baranello","year":"2024","unstructured":"Baranello, G. & Neurodevelopment in SMA Working Group. The emerging spectrum of neurodevelopmental comorbidities in early-onset spinal muscular atrophy. Eur. J. Paediatr. Neurol. 48, 67\u201368 (2024).","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"1224_CR172","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/dmcn.16461","volume":"68","author":"C Brusa","year":"2026","unstructured":"Brusa, C. et al. Expressive language and social communication abilities in children with spinal muscular atrophy type 1. Dev. Med. Child Neurol. 68,\u00a0696\u2013705 (2026).","journal-title":"Dev. Med. Child Neurol."},{"key":"1224_CR173","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-12484-8","volume":"15","author":"B Buchignani","year":"2025","unstructured":"Buchignani, B. et al. Neurodevelopmental and mental disorders in children with type I and presymptomatic spinal muscular atrophy. Sci. Rep. 15, 26984 (2025).","journal-title":"Sci. Rep."},{"key":"1224_CR174","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.70183","author":"LV Rezende","year":"2026","unstructured":"Rezende, L. V., Ortega, A. B., Do Valle, D. A., Bara, T. S. & Cordeiro, M. L. Autism spectrum disorder in children with spinal muscular atrophy type 1: case series. Dev. Med. Child Neurol. https:\/\/doi.org\/10.1111\/dmcn.70183 (2026).","journal-title":"Dev. Med. Child Neurol."},{"key":"1224_CR175","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1111\/dmcn.70112","volume":"68","author":"G Coratti","year":"2026","unstructured":"Coratti, G., Buchignani, B. & Mercuri, E. Cognitive and neurodevelopmental disorders in spinal muscular atrophy type I at the time of disease-modifying therapies. Dev. Med. Child Neurol. 68,\u00a0909-915 (2026).","journal-title":"Dev. Med. Child Neurol."},{"key":"1224_CR176","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/NEN.0000000000000144","volume":"74","author":"BN Harding","year":"2015","unstructured":"Harding, B. N. et al. Spectrum of neuropathophysiology in spinal muscular atrophy type I. J. Neuropathol. Exp. Neurol. 74, 15\u201324 (2015).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"1224_CR177","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1093\/brain\/awaf336","volume":"149","author":"F Gerstner","year":"2026","unstructured":"Gerstner, F. et al. Cerebellar pathology contributes to neurodevelopmental deficits in spinal muscular atrophy. Brain 149, 840\u2013855 (2026).","journal-title":"Brain"},{"key":"1224_CR178","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/ana.25549","volume":"86","author":"RH Mendonca","year":"2019","unstructured":"Mendonca, R. H. et al. Severe brain involvement in 5q spinal muscular atrophy type 0. Ann. Neurol. 86, 458\u2013462 (2019).","journal-title":"Ann. Neurol."},{"key":"1224_CR179","doi-asserted-by":"publisher","first-page":"175628642311543","DOI":"10.1177\/17562864231154335","volume":"16","author":"M Ngawa","year":"2023","unstructured":"Ngawa, M., Dal Farra, F., Marinescu, A. D. & Servais, L. Longitudinal developmental profile of newborns and toddlers treated for spinal muscular atrophy. Ther. Adv. Neurol. Disord. 16, 17562864231154335 (2023).","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"1224_CR180","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3390\/cancers17030416","volume":"17","author":"U Tosi","year":"2025","unstructured":"Tosi, U. et al. Neurocognitive safety of endoscopic colloid cyst resection: paired pre- and post-operative cognitive function from an exploratory cohort. Cancers (Basel) 17, 416 (2025).","journal-title":"Cancers (Basel)"},{"key":"1224_CR181","first-page":"226","volume":"4","author":"M Vitale","year":"2022","unstructured":"Vitale, M. et al. Best practices for the orthopaedic care of children with spinal muscular atrophy: a consensus statement from the european neuromuscular centre standard of care orthopaedic working group. J. Pediatr. Orthop. Soc. North Am. 4, 226\u2013232 (2022).","journal-title":"J. Pediatr. Orthop. Soc. North Am."},{"key":"1224_CR182","doi-asserted-by":"publisher","first-page":"gkag484","DOI":"10.1093\/nar\/gkag484","volume":"10","author":"K Ling","year":"2026","unstructured":"Ling, K. et al. Enhanced splicing modulation by NMA-modified antisense oligonucleotides. Nucleic Acids Res.10, gkag484 (2026).","journal-title":"Nucleic Acids Res."},{"key":"1224_CR183","unstructured":"Shieh, P. et al. The SOLAR study: phase 3 study to evaluate the efficacy and safety of salanersen in participants aged 15\u201360 years with spinal muscular atrophy (SMA). In Proc. Muscular Dystrophy Association Conference 2026 (2026)."},{"key":"1224_CR184","doi-asserted-by":"publisher","first-page":"4848","DOI":"10.1016\/j.ymthe.2025.06.028","volume":"33","author":"H Duan","year":"2025","unstructured":"Duan, H. et al. Gene therapy with covalently closed-end AAV vector for spinal muscular atrophy. Mol. Ther. 33, 4848\u20134857 (2025).","journal-title":"Mol. Ther."},{"key":"1224_CR185","doi-asserted-by":"publisher","unstructured":"Ngu, L. H. et al. Safety and efficacy of vesemnogene lantuparvovec, an AAV-based gene therapy for spinal muscular atrophy in children less than 24 months of age in low-middle income countries. First interim report as of April 2025. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2025.04.13.25325764 (2025).","DOI":"10.1101\/2025.04.13.25325764"},{"key":"1224_CR186","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1651-2227.2006.tb02379.x","volume":"450","author":"WHO Multicentre Growth Reference Study Group.","year":"2006","unstructured":"WHO Multicentre Growth Reference Study Group. WHO Motor Development Study: windows of achievement for six gross motor development milestones. Acta Paediatr. Suppl. 450, 86\u201395 (2006).","journal-title":"Acta Paediatr. Suppl."},{"key":"1224_CR187","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1097\/CM9.0000000000003210","volume":"137","author":"X Ma","year":"2024","unstructured":"Ma, X. et al. Treatment of SMA type 1 infants using a single-dose AAV9-mediated gene therapy via intrathecal injection of GC101: an open-label, single-arm study. Chin. Med. J. (Engl.) 137, 1976\u20131978 (2024).","journal-title":"Chin. Med. J. (Engl.)"},{"key":"1224_CR188","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s12519-025-00955-x","volume":"21","author":"XW Ma","year":"2025","unstructured":"Ma, X. W. et al. Single-dose GC101 gene therapy for spinal muscular atrophy types II and III: an open-label single-arm study. World J. Pediatr. 21, 935\u2013940 (2025).","journal-title":"World J. Pediatr."},{"key":"1224_CR189","first-page":"230","volume":"24","author":"K Patel","year":"2005","unstructured":"Patel, K., Macharia, R. & Amthor, H. Molecular mechanisms involving IGF-1 and myostatin to induce muscle hypertrophy as a therapeutic strategy for Duchenne muscular dystrophy. Acta Myol. 24, 230\u2013241 (2005).","journal-title":"Acta Myol."},{"key":"1224_CR190","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1097\/01.bor.0000184163.61558.ca","volume":"17","author":"KR Wagner","year":"2005","unstructured":"Wagner, K. R. Muscle regeneration through myostatin inhibition. Curr. Opin. Rheumatol. 17, 720\u2013724 (2005).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1224_CR191","doi-asserted-by":"publisher","first-page":"e209151","DOI":"10.1212\/WNL.0000000000209151","volume":"102","author":"TO Crawford","year":"2024","unstructured":"Crawford, T. O. et al. Safety and efficacy of apitegromab in patients with spinal muscular atrophy types 2 and 3: the phase 2 TOPAZ study. Neurology 102, e209151 (2024).","journal-title":"Neurology"},{"key":"1224_CR192","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S1474-4422(25)00225-X","volume":"24","author":"TO Crawford","year":"2025","unstructured":"Crawford, T. O. et al. Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 24, 727\u2013739 (2025).","journal-title":"Lancet Neurol."},{"key":"1224_CR193","doi-asserted-by":"publisher","first-page":"fcac324","DOI":"10.1093\/braincomms\/fcac324","volume":"5","author":"M Stam","year":"2023","unstructured":"Stam, M. et al. Randomized double-blind placebo-controlled crossover trial with pyridostigmine in spinal muscular atrophy types 2\u20134. Brain Commun. 5, fcac324 (2023).","journal-title":"Brain Commun."},{"key":"1224_CR194","doi-asserted-by":"publisher","first-page":"eadk9109","DOI":"10.1126\/scitranslmed.adk9109","volume":"16","author":"M Skov","year":"2024","unstructured":"Skov, M. et al. The ClC-1 chloride channel inhibitor NMD670 improves skeletal muscle function in rat models and patients with myasthenia gravis. Sci. Transl. Med. 16, eadk9109 (2024).","journal-title":"Sci. Transl. Med."},{"key":"1224_CR195","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/acn3.52252","volume":"12","author":"TS Gronnebaek","year":"2025","unstructured":"Gronnebaek, T. S. et al. Neuromuscular transmission deficits in patients with CMT and ClC-1 inhibition in CMT animal models. Ann. Clin. Transl. Neurol. 12, 320\u2013331 (2025).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1224_CR196","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1093\/brain\/awaf074","volume":"148","author":"CM Simon","year":"2025","unstructured":"Simon, C. M. et al. Proprioceptive synaptic dysfunction is a key feature in mice and humans with spinal muscular atrophy. Brain 148, 2797\u20132811 (2025).","journal-title":"Brain"},{"key":"1224_CR197","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/nn.4561","volume":"20","author":"EV Fletcher","year":"2017","unstructured":"Fletcher, E. V. et al. Reduced sensory synaptic excitation impairs motor neuron function via Kv2.1 in spinal muscular atrophy. Nat. Neurosci. 20, 905\u2013916 (2017).","journal-title":"Nat. Neurosci."},{"key":"1224_CR198","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/s41591-024-03484-8","volume":"31","author":"G Prat-Ortega","year":"2025","unstructured":"Prat-Ortega, G. et al. First-in-human study of epidural spinal cord stimulation in individuals with spinal muscular atrophy. Nat. Med. 31, 1246\u20131256 (2025).","journal-title":"Nat. Med."},{"key":"1224_CR199","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S0140-6736(25)00048-0","volume":"405","author":"L Servais","year":"2025","unstructured":"Servais, L., Dangouloff, T., Muntoni, F., Scoto, M. & Baranello, G. Spinal muscular atrophy in the UK: the human toll of slow decisions. Lancet 405, 619\u2013620 (2025).","journal-title":"Lancet"},{"key":"1224_CR200","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1001\/jamapediatrics.2024.0492","volume":"178","author":"O Schwartz","year":"2024","unstructured":"Schwartz, O. et al. Clinical effectiveness of newborn screening for spinal muscular atrophy: a nonrandomized controlled trial. JAMA Pediatr. 178, 540\u2013547 (2024).","journal-title":"JAMA Pediatr."},{"key":"1224_CR201","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/jnnp-2021-326344","volume":"92","author":"ST Shih","year":"2021","unstructured":"Shih, S. T., Farrar, M. A., Wiley, V. & Chambers, G. Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis. J. Neurol. Neurosurg. Psychiatry 92, 1296\u20131304 (2021).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1224_CR202","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/j.jval.2022.06.010","volume":"25","author":"R Velikanova","year":"2022","unstructured":"Velikanova, R. et al. Cost-effectiveness of newborn screening for spinal muscular atrophy in the Netherlands. Value Health 25, 1696\u20131704 (2022).","journal-title":"Value Health"},{"key":"1224_CR203","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03927-6","volume":"20","author":"A Pace","year":"2025","unstructured":"Pace, A. et al. A cost\u2013utility analysis of newborn screening for spinal muscular atrophy in Canada. Orphanet J. Rare Dis. 20, 428 (2025).","journal-title":"Orphanet J. Rare Dis."},{"key":"1224_CR204","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.nmd.2023.11.013","volume":"34","author":"T Dangouloff","year":"2024","unstructured":"Dangouloff, T. et al. Cost-effectiveness of spinal muscular atrophy newborn screening based on real-world data in Belgium. Neuromuscul. Disord. 34, 61\u201367 (2024).","journal-title":"Neuromuscul. Disord."},{"key":"1224_CR205","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jpeds.2020.07.033","volume":"227","author":"A Jalali","year":"2020","unstructured":"Jalali, A. et al. Cost-effectiveness of nusinersen and universal newborn screening for spinal muscular atrophy. J. Pediatr. 227, 274\u2013280.e2 (2020).","journal-title":"J. Pediatr."},{"key":"1224_CR206","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1007\/s00431-025-06560-4","volume":"184","author":"AK Mittal","year":"2025","unstructured":"Mittal, A. K. et al. Economic evidence on the cost-effectiveness of newborn screening for spinal muscular atrophy: a systematic review. Eur. J. Pediatr. 184, 774 (2025).","journal-title":"Eur. J. Pediatr."},{"key":"1224_CR207","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-04150-z","volume":"21","author":"M Yousefi","year":"2025","unstructured":"Yousefi, M. et al. Economic evaluations of disease-modifying therapies for spinal muscular atrophy: a systematic literature review. Orphanet J. Rare Dis. 21, 10 (2025).","journal-title":"Orphanet J. Rare Dis."},{"key":"1224_CR208","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejpn.2024.08.006","volume":"53","author":"EF Tizzano","year":"2024","unstructured":"Tizzano, E. F. et al. Outcomes for patients in the RESTORE registry with spinal muscular atrophy and four or more SMN2gene copies treated with onasemnogene abeparvovec. Eur. J. Paediatr. Neurol. 53, 18\u201324 (2024).","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"1224_CR209","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/jpc.16340","volume":"59","author":"D Yang","year":"2023","unstructured":"Yang, D., Ruan, Y. & Chen, Y. Safety and efficacy of gene therapy with onasemnogene abeparvovec in the treatment of spinal muscular atrophy: a systematic review and meta-analysis. J. Paediatr. Child Health 59, 431\u2013438 (2023).","journal-title":"J. Paediatr. Child Health"}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01224-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01224-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01224-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T12:03:18Z","timestamp":1787832198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01224-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":209,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1224"],"URL":"https:\/\/doi.org\/10.1038\/s41582-026-01224-9","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"26 May 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.M. reports funding to his institution to support clinical research from Biogen, Roche and Novartis; and having received personal advisory fees from Biogen, Roche, Novartis and Scholar Rock. R.S.F. reports funding to his institution to support clinical research from Biogen, Genentech\/Roche, Novartis and Scholar Rock; spinal muscular atrophy (SMA) study (APNCR) group support from Cure SMA; and having received personal advisory fees from Biogen, Genentech\/Roche, Novartis and Scholar Rock, and licensing fees from the Children\u2019s Hospital of Philadelphia. F.M. reports funding to his institution to support clinical research from Biogen, Roche and Novartis; and having received personal advisory fees from Biogen, Roche, Novartis and Scholar Rock.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}